Matteo S. Carlino
The University of Sydney(AU)Blacktown & Mount Druitt Hospital(AU)Westmead Hospital(AU)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Melanoma and MAPK Pathways, CAR-T cell therapy research, Immunotherapy and Immune Responses, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma(2015)8,054 cited
- → Pembrolizumab versus Ipilimumab in Advanced Melanoma(2015)5,779 cited
- → Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2017)5,337 cited
- → Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma(2019)3,640 cited
- → Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors(2018)2,518 cited
- → Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma(2018)1,816 cited
- → Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial